CytomX Therapeutics, Inc. (CTMX) CEO Sells $461,365.60 in Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy sold 19,120 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $24.13, for a total transaction of $461,365.60. Following the completion of the transaction, the chief executive officer now owns 23,365 shares of the company’s stock, valued at $563,797.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) opened at 21.50 on Monday. The stock’s market capitalization is $792.64 million. CytomX Therapeutics, Inc. has a 52 week low of $9.85 and a 52 week high of $24.67. The company has a 50-day moving average of $17.37 and a 200-day moving average of $15.69.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.30). The firm had revenue of $8.75 million for the quarter, compared to the consensus estimate of $4.95 million. CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. On average, analysts anticipate that CytomX Therapeutics, Inc. will post ($1.47) EPS for the current year.

WARNING: “CytomX Therapeutics, Inc. (CTMX) CEO Sells $461,365.60 in Stock” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://stocknewstimes.com/2017/10/09/cytomx-therapeutics-inc-ctmx-ceo-sells-461365-60-in-stock.html.

A number of equities analysts have recently commented on CTMX shares. Bank of America Corporation raised their price objective on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, October 4th. Nomura raised their price objective on shares of CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a research report on Wednesday, October 4th. Wedbush set a $37.00 price objective on shares of CytomX Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 4th. Cowen and Company reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research note on Tuesday, August 8th. Finally, Jefferies Group LLC set a $25.00 target price on shares of CytomX Therapeutics and gave the company a “buy” rating in a research note on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $32.67.

Several hedge funds and other institutional investors have recently bought and sold shares of CTMX. Legal & General Group Plc boosted its position in shares of CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 1,434 shares during the last quarter. First Quadrant L P CA bought a new position in shares of CytomX Therapeutics during the 2nd quarter valued at approximately $160,000. Cubist Systematic Strategies LLC bought a new position in shares of CytomX Therapeutics during the 2nd quarter valued at approximately $174,000. Goldman Sachs Group Inc. bought a new position in shares of CytomX Therapeutics during the 1st quarter valued at approximately $190,000. Finally, Voya Investment Management LLC bought a new position in shares of CytomX Therapeutics during the 2nd quarter valued at approximately $203,000. Hedge funds and other institutional investors own 59.97% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply